Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Cyclophosphamate

Small molecule · developed by Cellectar Biosciences

Phase 3 Most advanced trial
CLRB Developer
1 Registered trials

What is Cyclophosphamate?

Cyclophosphamate is named in trial records for the treatment of Waldenstrom Macroglobulinemia, including refractory, recurrent and nodal-disease settings.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Oncology
Developer
Cellectar Biosciences, Inc. (CLRB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07766421 Phase 3 Waldenstrom Macroglobulinaemia Not yet recruiting CLRB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Waldenstrom MacroglobulinaemiaWaldenstrom MacroglobulinemiaWaldenstrom Macroglobulinemia With Nodal DiseaseWaldenstrom's Macroglobulinaemia RefractoryWaldenstrom's Macroglobulinemia Recurrent

More from Cellectar Biosciences

Iodine I 124 Iopofosine Phase 2 Iodine I 125 Iopofosine Phase 1 Iodine I 131 Iopofosine Phase 3 NM404 Phase 1 NOV-002 Phase 3 NOV-205 Phase 2

Follow CLRB, the company behind Cyclophosphamate

See CLRB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLRB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.